Abstract
Since it has been widely demonstrated that platinum-based drugs, like cisplatin, carboplatin and oxaliplatin, bind preferentially to guanine in N7 position and that telomerase assemblage includes a RNA portion rich in guanine, we previously designed and synthesized a series of new complexes with a cytotoxic [Pt(II)Cl2] moiety, with the aim of selecting carrier ligands able to inhibit telomerase enzyme. Among these compounds, [cis-dichloropyridine-5-isoquinolinesulfonic acid Pt(II)], named Ptquin8, showed the most significant inhibition of telomerase in a cell-free biochemical assay. In this paper, we report the biological effects of Ptquin8 on in vitro tumor model (MCF-7). This complex is able to reduce telomerase activity from 12 to 46%, in a concentration range between 10−9 and 10−5 M after 24 h continuous treatment. Moreover, Ptquin8 shows significant cytotoxicity after 10 days of continuous treatment only at concentrations higher than 10−5 M. The determination of residual telomere length confirmed the inhibition of telomerase action. This induced a progressive reduction of the cell proliferative capacity, and the appearance of an elevated number of apoptotic cells after 18 days. RT-PCR analysis of telomerase RNA components excluded any interaction of the compound at genomic level. The biochemical effects of Ptquin8 were also evaluated on non-neoplastic NIH3T3 cells, that are able to down-regulate telomerase activity as a consequence of the confluence contact inhibition. In this cell model, the reactivation of telomerase due to re-seeding at lower density was significantly inhibited by Ptquin8 in a dose-dependent manner. These results highlight a possible role of Ptquin8 as a selective anti-telomerase tool for cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiyama M, Horiguchi-Yamada J, Saito S, Hoshi Y, Yamada O, Mizoguchi H, Yamada H. 1999 Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur J Cancer 35(2): 309–315.
Bradford M. 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of proteindye binding. Anal Biochem 72: 248–254.
Burger AM, Double JA, Newell DR. 1997 Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33, 638–644.
Campisi J. 1997 Aging and cancer: the double-edged sword of replicative senescence. J Am Geriatr Soc 45: 482–488.
Campisi J. 1997. The biology of replicative senescence. Eur J Cancer 33: 703–709.
Cavigiolio G, Benedetto L, Boccaleri E, Colangelo D, Viano I, Osella D. 2000 Pt(II) complexes with different N-donor aromatic ligands for specific inhibition of telomerase. Inorganica Chimica Acta 305, 61–68.
Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E, Graziani G. 1997 Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3, 579–585.
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J et al. 1995 The RNA component of human telomerase. Science 269, 1236–1241.
Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA. 1999 Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5, 1164–1170.
Holt SE, Wright WE, Shay JW. 1996 Regulation of telomerase activity in immortal call lines. Mol Cell Biol 16(6): 2932–2939.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. 1994 Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011–2015.
Lejnine S, Makarov VL, Langmore JP. 1995. Conserved nucleoprotein structure at the ends of vertebrate and invertebrate chromosomes. Proc Natl Acad Sci USA; 92, 2393–2397.
Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. 1997 Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276, 561–567.
Lippert B (ed.) 1999. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. Weinheim: Wiley – VCH.
Liu JP 1999 Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 13, 2091–2104.
Melana SM, Holland JF, Pogo BG. 1998 Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin Cancer Res 4, 693–696.
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. 1997 Telomerase catalytic subunit homologues from fission yeast and human. Science 277, 955–959.
Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR. 1996 Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 14, 615–619.
Ogino H, Nakabayashi K, Suzuki M, Takahashi E, Fujii M, Suzuki T, Ayusawa D. 1998 Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. Biochem Biophys Res Commun 248, 223–227.
Parkinson EK, Newbold RF, Keith WN. 1997 The genetic basis of human keratinocyte immortalization in squamous cell carcinoma development: the role of telomerase reactivation. Eur J Cancer 33(5), 727–734.
Sherman SE and Lippard SJ. 1987 Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87, 1153–1181.
Strahl C and Blackburn EH. 1994 The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 22, 893–900.
Strahl C and Blackburn EH. 1996 Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16, 53–65.
Wong E, Christen MG. 1999 Current status of platinum-based antitumor drugs. Chem. Rev. 99, 2451–2466.
Yegorov YE, Chernov DN, Akimov SS, Bolsheva NL, Krayevsky AA, Zelenin AV. 1996 Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett 389, 115–118.
Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, Tamaya T. 1998 Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 58, 5406–5410.
Zhang RG, Zhang RP, Wang XW, Xie H 2002 Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Research 12: 55–62
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Colangelo, D., Ghiglia, A.L., Viano, I. et al. Cis-[Pt(Cl)2(pyridine)(5-SO3H-isoquinoline)] complex, a selective inhibitor of telomerase enzymea . Biometals 16, 553–560 (2003). https://doi.org/10.1023/A:1023428315746
Issue Date:
DOI: https://doi.org/10.1023/A:1023428315746